Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 31;10(4):822.
doi: 10.3390/biomedicines10040822.

The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma

Madison Ernst  1 , Alessio Giubellino  1
Affiliations
Review

The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma

Madison Ernst et al. Biomedicines. .

Abstract

Malignant melanoma is the leading cause of death among cutaneous malignancies. While its incidence is increasing, the most recent cancer statistics show a small but clear decrease in mortality rate. This trend reflects the introduction of novel and more effective therapeutic regimens, including the two cornerstones of melanoma therapy: immunotherapies and targeted therapies. Immunotherapies exploit the highly immunogenic nature of melanoma by modulating and priming the patient's own immune system to attack the tumor. Treatments combining immunotherapies with targeted therapies, which disable the carcinogenic products of mutated cancer cells, have further increased treatment efficacy and durability. Toxicity and resistance, however, remain critical challenges to the field. The present review summarizes past treatments and novel therapeutic interventions and discusses current clinical trials and future directions.

Keywords: combined therapies; immunotherapy; metastatic melanoma; targeted therapy; tumor relapse; tumor resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. American Cancer Society . Cancer Facts and Figures 2022. American Cancer Society Inc.; Atlanta, GA, USA: 2022.
    1. Alexandrov L.B., Kim J., Haradhvala N.J., Huang M.N., Ng A.W.T., Wu Y., Boot A., Covington K.R., Gordenin D.A., Bergstrom E.N., et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101. doi: 10.1038/s41586-020-1943-3. - DOI - PMC - PubMed
    1. Chapman P.B., Einhorn L.H., Meyers M.L., Saxman S., Destro A.N., Panageas H.S., Begg C.B., Agarwala S.S., Schuchter L.M., Ernstoff M.S., et al. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma. J. Clin. Oncol. 1999;17:2745. doi: 10.1200/JCO.1999.17.9.2745. - DOI - PubMed
    1. Bajetta E., Del Vecchio M., Nova P., Fusi A., Daponte A., Sertoli M.R., Queirolo P., Taveggia P., Bernengo M.G., Legha S.S., et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma. Ann. Oncol. 2006;17:571–577. doi: 10.1093/annonc/mdl007. - DOI - PubMed
    1. Song X., Zhao Z., Barber B., Farr A.M., Ivanov B., Novich M. Overall survival in patients with metastatic melanoma. Curr. Med. Res. Opin. 2015;31:987–991. doi: 10.1185/03007995.2015.1021904. - DOI - PubMed

LinkOut - more resources